7 T Magnetic Resonance Spectroscopic Imaging in Multiple Sclerosis: How Does Spatial Resolution Affect the Detectability of Metabolic Changes in Brain Lesions?

HEČKOVÁ, Eva, Bernhard STRASSER, Gilbert HANGEL, Michal POVAŽAN, Assunta DAL-BIANCO, Paulus ROMMER, Petr BEDNAŘÍK, Stephan GRUBER, Fritz LEUTMEZER, Hans LASSMANN, Siegfried TRATTNIG and Wolfgang BOGNER. 7 T Magnetic Resonance Spectroscopic Imaging in Multiple Sclerosis: How Does Spatial Resolution Affect the Detectability of Metabolic Changes in Brain Lesions? Investigative Radiology. 2018. Available from: https://dx.doi.org/10.1097/RLI.0000000000000531.

Basic information

• Original name: 7 T Magnetic Resonance Spectroscopic Imaging in Multiple Sclerosis: How Does Spatial Resolution Affect the Detectability of Metabolic Changes in Brain Lesions?
• Name (in English): 7 T Magnetic Resonance Spectroscopic Imaging in Multiple Sclerosis: How Does Spatial Resolution Affect the Detectability of Metabolic Changes in Brain Lesions?
• Authors: HEČKOVÁ, Eva, Bernhard STRASSER, Gilbert HANGEL, Michal POVAŽAN, Assunta DAL-BIANCO, Paulus ROMMER, Petr BEDNAŘÍK, Stephan GRUBER, Fritz LEUTMEZER, Hans LASSMANN, Siegfried TRATTNIG and Wolfgang BOGNER.
• Edition: Investigative Radiology, 2018.

Other information

• Type of outcome: Article in a journal
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Doi: http://dx.doi.org/10.1097/RLI.0000000000000531
• UT WoS: 000461882000008
• Tags: International impact, Reviewed

Abstract

Abstract Objectives The aim of this study was to assess the utility of increased spatial resolution of magnetic resonance spectroscopic imaging (MRSI) at 7 T for the detection of neurochemical changes in multiple sclerosis (MS)–related brain lesions. Materials and Methods This prospective, institutional review board–approved study was performed in 20 relapsing-remitting MS patients (9 women/11 men; mean age ± standard deviation, 30.8 ± 7.7 years) after receiving written informed consent. Metabolic patterns in MS lesions were compared at 3 different spatial resolutions of free induction decay MRSI with implemented parallel imaging acceleration: 2.2 × 2.2 × 8 mm3; 3.4 × 3.4 × 8 mm3; and 6.8 × 6.8 × 8 mm3 voxel volumes, that is, matrix sizes of 100 × 100, 64 × 64, and 32 × 32, respectively. The quality of data was assessed by signal-to-noise ratio and Cramér-Rao lower bounds. Statistical analysis was performed using Wilcoxon signed-rank tests with correction for multiple testing. Results Seventy-seven T2-hyperintense MS lesions were investigated (median volume, 155.7 mm3; range, 10.8–747.0 mm3). The mean metabolic ratios in lesions differed significantly between the 3 MRSI resolutions (ie, 100 × 100 vs 64 × 64, 100 × 100 vs 32 × 32, and 64 × 64 vs 32 × 32; P < 0.001). With the ultra-high resolution (100 × 100), we obtained 40% to 80% higher mean metabolic ratios and 100% to 150% increase in maximum metabolic ratios in the MS lesions compared with the lowest resolution (32 × 32), while maintaining good spectral quality (signal-to-noise ratio >12, Cramér-Rao lower bounds <20%) and measurement time of 6 minutes. There were 83% of MS lesions that showed increased myo-inositol/N-acetylaspartate with the 100 × 100 resolution, but only 66% were distinguishable with the 64 × 64 resolution and 35% with the 32 × 32 resolution. Conclusions Ultra-high-resolution MRSI (~2 × 2 × 8 mm3 voxel volume) can detect metabolic alterations in MS, which cannot be recognized by conventional MRSI resolutions, within clinically acceptable time.

Abstract (in English)

Abstract Objectives The aim of this study was to assess the utility of increased spatial resolution of magnetic resonance spectroscopic imaging (MRSI) at 7 T for the detection of neurochemical changes in multiple sclerosis (MS)–related brain lesions. Materials and Methods This prospective, institutional review board–approved study was performed in 20 relapsing-remitting MS patients (9 women/11 men; mean age ± standard deviation, 30.8 ± 7.7 years) after receiving written informed consent. Metabolic patterns in MS lesions were compared at 3 different spatial resolutions of free induction decay MRSI with implemented parallel imaging acceleration: 2.2 × 2.2 × 8 mm3; 3.4 × 3.4 × 8 mm3; and 6.8 × 6.8 × 8 mm3 voxel volumes, that is, matrix sizes of 100 × 100, 64 × 64, and 32 × 32, respectively. The quality of data was assessed by signal-to-noise ratio and Cramér-Rao lower bounds. Statistical analysis was performed using Wilcoxon signed-rank tests with correction for multiple testing. Results Seventy-seven T2-hyperintense MS lesions were investigated (median volume, 155.7 mm3; range, 10.8–747.0 mm3). The mean metabolic ratios in lesions differed significantly between the 3 MRSI resolutions (ie, 100 × 100 vs 64 × 64, 100 × 100 vs 32 × 32, and 64 × 64 vs 32 × 32; P < 0.001). With the ultra-high resolution (100 × 100), we obtained 40% to 80% higher mean metabolic ratios and 100% to 150% increase in maximum metabolic ratios in the MS lesions compared with the lowest resolution (32 × 32), while maintaining good spectral quality (signal-to-noise ratio >12, Cramér-Rao lower bounds <20%) and measurement time of 6 minutes. There were 83% of MS lesions that showed increased myo-inositol/N-acetylaspartate with the 100 × 100 resolution, but only 66% were distinguishable with the 64 × 64 resolution and 35% with the 32 × 32 resolution. Conclusions Ultra-high-resolution MRSI (~2 × 2 × 8 mm3 voxel volume) can detect metabolic alterations in MS, which cannot be recognized by conventional MRSI resolutions, within clinically acceptable time.